Dock4.0を用いた非ステロイド性抗炎症剤のCOX1およびCOX2に対する結合モードに関する研究

  • 赤穂 栄一
    神戸学院大学薬学部 〒651-2180 神戸市西区伊川谷町有瀬518
  • 藤川 智香子
    神戸学院大学薬学部 〒651-2180 神戸市西区伊川谷町有瀬518
  • RUNION Howell I.
    School of Pharmacy, University of the Pacific 751 Brookside Road, Stockton, CA 95211 USA
  • HILL Craig R.
    School of Pharmacy, University of the Pacific 751 Brookside Road, Stockton, CA 95211 USA
  • 中野 英彦
    姫路工業大学工学部応用化学科 〒671-2201 姫路市書写2167

書誌事項

タイトル別名
  • A Study on Binding Modes of Nonsteroidal Anti-inflammatory Drugs to COX1 and COX2 as Obtained by Dock4.0.
  • Study on Binding Modes of Nonsteroidal Anti-inflammatory Drugs to COX1 and COX2 as Obtained by Dock4.0

この論文をさがす

抄録

Nonsteroidal anti-inflammatory drugs (NSAIDs) which selectively inhibit COX2 without affecting an enzyme activity of COX 1 would be an ideal anti-inflammatory drug. Thus an attempt was made to examine those binding modes of NSAIDs against COX1 and COX2 in terms of hydrogen bond and binding energy by utilizing Dock4.0. It was shown that binding mode to COX2 selective NSAIDs coincided with the result reported in the in vitro study by R.S. Spangler (Seminars in Arthritis and Rheumatism, 26, 435-446 (1996)). Thus, it can be said that there is a fairly good correlation between the Dock4.0 results and those reported in the in vitro study. As far as the binding mode of COX1 selective NSAIDs is concerned one corresponded to the in vitro study reported by R.S. Spangler, another did not and a third presented a mediocre conformity. It was also shown that there existed one to three H-bonds with the net total being at least twelve when NSAIDs such as nabumetone, meclofenamate, niflumic acid, indomethacin, sulindac, and flurbiprofen were bound to COX2. Amino acid residues involved in such hydrogen bonds were Phe A518, Arg A120, Tyr A385, His A90, Tyr A355. Met A522, Ser A353, Gln A192, Leu A352, and Arg A513. Phe A518 and His A90 were reported by R. G. Kurumbail et al. (Nature, 384, 644-648 (1996)) but the rest of the amino acid residues were not.

収録刊行物

参考文献 (28)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ